CRL Charles River Laboratories International PE ratio, current and historical analysis
- Stocks
- Healthcare
- NYSE: CRL
- PE Ratio
The current PE ratio of CRL cannot be calculated, as the latest EPS of -$0.6 is negative. Charles River Laboratories International's last PE ratio on record was 930.8 in December 2024.
CRL PE ratio history
The mean historical PE ratio of Charles River Laboratories International over the last ten years is 54.1. Looking back at the last ten years, CRL's PE ratio peaked in the Dec 2024 quarter at 930.8, with a price of $186.16 and an EPS of $0.2. The Apr 2023 quarter marked the lowest point at 20.68, with a price of $201.82 and an EPS of $9.76.
Charles River Laboratories International PE ratio by year
Maximum annual increase: 3,550.2% in 2024
Maximum annual decrease: -52.08% in 2022
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | 930.8 | 3,550.2% | $186.16 | $0.2 |
| 2023 | 25.5 | 11.99% | $236.4 | $9.27 |
| 2022 | 22.77 | -52.08% | $217.9 | $9.57 |
| 2021 | 47.52 | 38.74% | $369.2 | $7.77 |
| 2020 | 34.25 | 16.54% | $251.71 | $7.35 |
| 2019 | 29.39 | 24.17% | $151.93 | $5.17 |
| 2018 | 23.67 | -43.78% | $111.72 | $4.72 |
| 2017 | 42.1 | 81.78% | $109.45 | $2.6 |
| 2016 | 23.16 | -7.17% | $76.19 | $3.29 |
| 2015 | 24.95 | 5.54% | $80.08 | $3.21 |
| 2014 | 23.64 | -4.68% | $64.29 | $2.72 |
| 2013 | 24.8 | 36.49% | $53.33 | $2.15 |
| 2012 | 18.17 | 43.64% | $36.88 | $2.03 |
| 2011 | 12.65 | N/A | $27.33 | $2.16 |
| 2010 | N/A | N/A | $35.7 | -$5.38 |
Charles River Laboratories International PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2025 | N/A | N/A | $155.55 | -$0.6 |
| Dec 2024 | 930.8 | 3,679.13% | $186.16 | $0.2 |
| Sep 2024 | 24.63 | 0.29% | $198.31 | $8.05 |
| Jun 2024 | 24.56 | -22.5% | $206.58 | $8.41 |
| Mar 2024 | 31.69 | 24.27% | $270.95 | $8.55 |
| Dec 2023 | 25.5 | 21.03% | $236.4 | $9.27 |
| Sep 2023 | 21.07 | -4.79% | $195.98 | $9.3 |
| Jul 2023 | 22.13 | 7.01% | $210.25 | $9.5 |
| Apr 2023 | 20.68 | -9.18% | $201.82 | $9.76 |
| Dec 2022 | 22.77 | 4.69% | $217.9 | $9.57 |
| Sep 2022 | 21.75 | -15.73% | $187.51 | $8.62 |
| Jun 2022 | 25.81 | -22.52% | $226.32 | $8.77 |
| Mar 2022 | 33.31 | -29.9% | $279.1 | $8.38 |
| Dec 2021 | 47.52 | -17.88% | $369.2 | $7.77 |
| Sep 2021 | 57.87 | 24.88% | $458.3 | $7.92 |
CRL Price vs fair value
CRL average PE ratio chart
CRL PE vs peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| TMO Thermo Fisher Scientific Inc | 24.66 | $159.1B |
| RGEN Repligen Corp | N/A | $7.1B |
| SCYX Scynexis Inc | N/A | $27.35M |
| CRL Charles River Laboratories International Inc | N/A | $7.58B |
Frequently asked questions
What is Charles River Laboratories International's PE ratio?
The current price to earnings ratio of CRL cannot be determined, as its EPS of -$0.6 is negative.
What is the 3-year average PE ratio for Charles River Laboratories International (CRL)?
As an average over the last 3 years, CRL stock has a PE ratio of 114.56.
What is the 5-year average PE ratio for Charles River Laboratories International (CRL)?
As an average over the last 5 years, CRL stock has a PE ratio of 81.36.
What is the highest PE ratio for CRL?
Over the last ten years, the Dec 2024 quarter recorded the highest quarterly PE ratio at 930.8.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.